Knight Therapeutics (TSE:GUD) Hits New 52-Week High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD) hit a new 52-week high on Thursday. The stock traded as high as C$11.84 and last traded at C$11.59, with a volume of 3,125 shares traded. The stock had previously closed at C$11.26.

Knight Therapeutics Price Performance

The company has a debt-to-equity ratio of 4.29, a current ratio of 2.28 and a quick ratio of 1.79. The stock has a market capitalization of C$1.16 billion, a price-to-earnings ratio of 78.40, a price-to-earnings-growth ratio of -1,013.50 and a beta of -0.51. The company has a 50-day simple moving average of C$10.53 and a two-hundred day simple moving average of C$8.61.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings results on Thursday, November 5th. The company reported C($0.03) earnings per share (EPS) for the quarter. The firm had revenue of C$136.74 million for the quarter. Knight Therapeutics had a net margin of 2.72% and a return on equity of 1.91%. On average, equities research analysts predict that Knight Therapeutics Inc. will post 0.10 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.